TSM

232.52

-2.6%↓

ORCL

255.62

+1.12%↑

ASML.US

689

-1.42%↓

IBM

250.47

-0.54%↓

NOW

904.5

-2.03%↓

TSM

232.52

-2.6%↓

ORCL

255.62

+1.12%↑

ASML.US

689

-1.42%↓

IBM

250.47

-0.54%↓

NOW

904.5

-2.03%↓

TSM

232.52

-2.6%↓

ORCL

255.62

+1.12%↑

ASML.US

689

-1.42%↓

IBM

250.47

-0.54%↓

NOW

904.5

-2.03%↓

TSM

232.52

-2.6%↓

ORCL

255.62

+1.12%↑

ASML.US

689

-1.42%↓

IBM

250.47

-0.54%↓

NOW

904.5

-2.03%↓

TSM

232.52

-2.6%↓

ORCL

255.62

+1.12%↑

ASML.US

689

-1.42%↓

IBM

250.47

-0.54%↓

NOW

904.5

-2.03%↓

Search

SS&C Technologies Holdings Inc

Avatud

SektorTehnoloogia

85.75 0.63

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

84.88

Max

85.88

Põhinäitajad

By Trading Economics

Sissetulek

-32M

181M

Müük

23M

1.5B

P/E

Sektori keskmine

26.871

71.636

Aktsiakasum

1.44

Dividenditootlus

1.17

Kasumimarginaal

11.784

Töötajad

26,800

EBITDA

-13M

345M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+16.51% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

1.17%

2.51%

Järgmine tulemuste avaldamine

23. okt 2025

Järgmine dividendimakse kuupäev

15. sept 2025

Järgmine aktsia dividendi kuupäev (ex-date)

2. sept 2025

Turustatistika

By TradingEconomics

Turukapital

486M

21B

Eelmine avamishind

85.12

Eelmine sulgemishind

85.75

Uudiste sentiment

By Acuity

50%

50%

185 / 407 Pingereas Technology

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

SS&C Technologies Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. aug 2025, 21:42 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

4. aug 2025, 21:21 UTC

Tulu
Suurimad hinnamuutused turgudel

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

4. aug 2025, 20:45 UTC

Tulu

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

4. aug 2025, 19:15 UTC

Suurimad hinnamuutused turgudel

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

4. aug 2025, 23:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. aug 2025, 23:41 UTC

Market Talk

Nikkei May Rise on Fed Stimulus Hopes

4. aug 2025, 23:28 UTC

Market Talk

Global Equities Roundup: Market Talk

4. aug 2025, 23:28 UTC

Market Talk

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

4. aug 2025, 21:30 UTC

Tulu

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4. aug 2025, 21:21 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

4. aug 2025, 21:18 UTC

Tulu

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

4. aug 2025, 20:25 UTC

Market Talk

India Hits Back Over Russian Oil Purchases -- Market Talk

4. aug 2025, 20:25 UTC

Tulu

Transocean 2Q Loss $938M >RIG

4. aug 2025, 20:25 UTC

Tulu

Transocean 2Q Loss/Shr $1.06 >RIG

4. aug 2025, 20:18 UTC

Tulu

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

4. aug 2025, 20:15 UTC

Tulu

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

4. aug 2025, 20:14 UTC

Tulu

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

4. aug 2025, 20:14 UTC

Tulu

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

4. aug 2025, 20:14 UTC

Tulu

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

4. aug 2025, 20:13 UTC

Tulu

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

4. aug 2025, 20:09 UTC

Tulu

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

4. aug 2025, 20:06 UTC

Tulu

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

4. aug 2025, 20:01 UTC

Tulu

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

4. aug 2025, 19:41 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

4. aug 2025, 19:28 UTC

Market Talk

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

4. aug 2025, 19:07 UTC

Market Talk

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

4. aug 2025, 18:27 UTC

Market Talk

Gold Climbs on Rate Cut Speculation -- Market Talk

Võrdlus sarnastega

Hinnamuutus

SS&C Technologies Holdings Inc Prognoos

Hinnasiht

By TipRanks

16.51% tõus

12 kuu keskmine prognoos

Keskmine 98.14 USD  16.51%

Kõrge 108 USD

Madal 88 USD

Põhineb 8 Wall Streeti analüütiku instrumendi SS&C Technologies Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

6

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

75.15 / 78.1Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Strong Bullish Evidence

Sentiment

By Acuity

185 / 407 Pingereas Tehnoloogia

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest SS&C Technologies Holdings Inc

SS&C Technologies Holdings, Inc., together with its subsidiaries, provides software products and software-enabled services to financial services and healthcare industries. The company owns and operates technology stack across securities accounting; front-office functions, such as trading and modeling; middle-office functions comprising portfolio management and reporting; back-office functions, such as accounting, performance measurement, reconciliation, reporting, processing and clearing, and compliance and tax reporting; and healthcare solutions consisting of claims adjudication, benefit management, care management, and business intelligence solutions. Its products and services allow professionals in the financial services and healthcare industries to automate complex business processes and are instrumental in helping its clients to manage information processing requirements. The company's software-enabled services include SS&C GlobeOp, Global Investor and Distribution Solutions, SS&C Retirement Solutions, Black Diamond Wealth Platform, CRM Solutions, Advent Managed Services, Advent Data Solutions, ALPS Advisors, and Virtual Data Rooms, as well as pharmacy, healthcare administration, and health outcomes optimization solutions. Its software products comprise portfolio/investment accounting and analytics software, portfolio management software, trading software, automation solutions, and banking and lending solutions, as well as research, analytics, risk, and training solutions. The company also provides professional services that includes consulting and implementation services consisting of initial system installation, conversion of historical data, and ongoing training and support, as well as product support services. It operates in the United States; Europe, the Middle East, and Africa; the Asia Pacific and Japan; Canada; and the Americas. The company was founded in 1986 and is headquartered in Windsor, Connecticut.